Related Experiment Video

Updated: May 17, 2026

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells
08:35

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells

Published on: June 12, 2017

Reactivation of autophagy ameliorates LMNA cardiomyopathy

Jason C Choi1, Howard J Worman

  • 1Department of Medicine and Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Autophagy
|October 10, 2012
PubMed

Insights

Mutations in the LMNA gene cause laminopathies, including dilated cardiomyopathy. This study found that inhibiting MTOR signaling improved heart function and enhanced autophagy in a mouse model, revealing a key mechanism in disease development.

Area of Science:

  • Molecular Biology
  • Cardiovascular Disease
  • Genetics

Background:

  • Mutations in the LMNA gene lead to laminopathies, a group of diseases affecting various tissues.
  • Dilated cardiomyopathy, often with skeletal muscle involvement (e.g., Emery-Dreifuss muscular dystrophy), is a common manifestation.
  • Emerging evidence suggests cell signaling defects contribute to laminopathy pathogenesis.

Purpose of the Study:

  • To investigate signaling pathway defects in a mouse model of Emery-Dreifuss muscular dystrophy caused by an Lmna mutation.
  • To determine the role of AKT-mechanistic target of rapamycin (MTOR) signaling in the observed cardiomyopathy.
  • To explore the relationship between MTOR signaling, autophagy, and cardiac function in this disease model.

Main Methods:

  • Utilized a mouse model with a point mutation in Lmna (Lmna (H222P/H222P)) that mimics human Emery-Dreifuss muscular dystrophy.
  • Assessed AKT-MTOR signaling pathway activity in the hearts of mutant mice.
  • Administered pharmacological interventions to modulate MTOR activity.
  • Evaluated fasting-induced autophagic responses in cardiac tissue.
  • Correlated changes in heart function with autophagy levels.

Main Results:

  • Hyperactivation of AKT-MTOR signaling was observed in the hearts of Lmna (H222P/H222P) mice.
  • Pharmacological inhibition of MTOR activity significantly ameliorated cardiomyopathy in these mice.
  • Fasting-induced autophagy was impaired in the hearts of Lmna (H222P/H222P) mice.
  • Improved cardiac function following MTOR blockade was associated with enhanced autophagy.

Conclusions:

  • Signaling defects, specifically hyperactivation of the AKT-MTOR pathway, contribute to the pathogenesis of dilated cardiomyopathy in LMNA mutations.
  • Impaired autophagy is a key consequence of these signaling defects.
  • Targeting MTOR signaling represents a potential therapeutic strategy for LMNA-related dilated cardiomyopathy by restoring autophagic function.

More Related Videos

Activating Autophagy by Aerobic Exercise in Mice08:44

Activating Autophagy by Aerobic Exercise in Mice

Published on: February 3, 2017

LAD-Ligation: A Murine Model of Myocardial Infarction08:23

LAD-Ligation: A Murine Model of Myocardial Infarction

Published on: October 14, 2009

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Delivery Pathways to the Lysosome01:36

Delivery Pathways to the Lysosome

Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...